Form D · Biotechnology
Sonoma Biotherapeutics, Inc.
South San Francisco, CA · CIK 0001877861
Offering snapshot reported Aug 11, 2021 · SEC filing
- Reported sold
- $265M Offering amount: $265M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 11, 2021 | Initial | $264,999,940 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-409599
Source: Form D, filed Aug 11, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Bluestone | Director, Executive, Promoter |
| Toni Hoover | Director |
| Richard Klausner | Director |
| Terry Rosen | Director |
| Maggie Wilderotter | Director |
| Fan Yu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
400 E. Jamie Ct., Suite 202
South San Francisco, CA, 94080
South San Francisco, CA, 94080